Drug
Pagibaximab
Pagibaximab: highest development phase Phase 2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pagibaximab (formerly BSYX-A110) NCT00631800 | Phase 2 | Staphylococcal Sepsis |
Latest
No recent events.
Follow Pagibaximab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.